DCPH News and Press, Deciphera Pharmaceuticals Inc. From 05/04/21

- First Quarter 2021 QINLOCK® Net Product Revenue of $20.0 Million; QINLOCK Approved in China and Hong Kong for Fourth-line GIST - - Top-line Results from INTRIGUE Phase 3 Study of QINLOCK in Patients with Second-line GIST Expected in the Fourth Quarter of 2021; Plans to ...

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its first quarter 2021 financial results on Tuesday, May 4, 2021. In connection with the earnings release, Deciphera’s management team will host a live conference call and webcast at 4:30 PM ET...

The China National Medical Products Administration ((NMPA)) has approved Zai Lab (ZLAB) and Deciphera Pharmaceuticals' (DCPH) New Drug Application ((NDA)) for Qinlock (ripretinib) for the treatment of adults with advanced gastrointestinal stromal tumors ((GIST)) who have received prior treatm...

China NMPA approval follows 2020 U.S. FDA approval for the treatment of patients with fourth-line GIST QINLOCK demonstrated a significant improvement in progression-free survival and a clinically meaningful benefit in overall survival compared to placebo in the pivotal Phase 3 I...

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the Barclays Global Healthcare Conference on March 9, 2021 at 1:50 PM ET. The conference will be held in a virtual meeting for...

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will participate in a fireside chat at the SVB Leerink 10 th Annual Global Healthcare Conference on February 25, 2021 at 4:20 PM ET. The conference will be held ...

DCPH has seen some early success with ripretinib in 4th line and later GIST. However, the key to the mint is to show positive data in INTRIGUE, in 2nd line GIST for imatinib-refractory patients, and compared to sunitinib. That data will be out sometime in late 2021. For furt...

Deciphera Pharmaceuticals ([[DCPH]] +3.9%) was raised to outperform from market perform by SVB Leerink citing the disparity between the recent share price weakness and pipeline progress.The price target at $70 per share represents a ~44.9% upside to the previous close, and Deciphera is tradin...

The following slide deck was published by Deciphera Pharmaceuticals, Inc. in conjunction with their 2021 Q1 earnings call. For further details see: Deciphera Pharmaceuticals, Inc. 2021 Q1 - Results - Earnings Call Presentation

Deciphera Pharmaceuticals, Inc. (DCPH) Q4 2020 Earnings Conference Call February 09, 2021, 16:30 PM ET Company Participants Jen Robinson - Vice President, Investor Relations Steven Hoerter - President and Chief Executive Officer Daniel Martin - Chief Commercial Officer Matthew Sherman - Chief...